BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang WJ, Zhang G, Luo HS, Liang LX, Huang D, Zhang FC. Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome. Gut Liver. 2016;10:382-390. [PMID: 26446924 DOI: 10.5009/gnl14319] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Noor-Mohammadi E, Ligon CO, Mackenzie K, Stratton J, Shnider S, Greenwood-Van Meerveld B. A Monoclonal Anti-Calcitonin Gene-Related Peptide Antibody Decreases Stress-Induced Colonic Hypersensitivity. J Pharmacol Exp Ther 2021;379:270-9. [PMID: 34620725 DOI: 10.1124/jpet.121.000731] [Reference Citation Analysis]
2 Gonzalez CG, Tankou SK, Cox LM, Casavant EP, Weiner HL, Elias JE. Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors. Sci Rep 2019;9:12460. [PMID: 31462662 DOI: 10.1038/s41598-019-48495-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ceuleers H, Van Spaendonk H, Hanning N, Heirbaut J, Lambeir AM, Joossens J, Augustyns K, De Man JG, De Meester I, De Winter BY. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World J Gastroenterol 2016; 22(47): 10275-10286 [PMID: 28058009 DOI: 10.3748/wjg.v22.i47.10275] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
4 Shukla R, Ghoshal U, Ranjan P, Ghoshal UC. Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis. J Neurogastroenterol Motil 2018;24:628-42. [PMID: 30347939 DOI: 10.5056/jnm18130] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
5 Yoon H. Mast Cell May Be the Master Key to Solve the Mystery of Pathogenesis of Irritable Bowel Syndrome. Gut Liver 2016;10:325-6. [PMID: 27114430 DOI: 10.5009/gnl16092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ren HX, Zhang FC, Luo HS, Zhang G, Liang LX. Role of mast cell-miR-490-5p in irritable bowel syndrome. World J Gastroenterol 2017; 23(1): 93-102 [PMID: 28104984 DOI: 10.3748/wjg.v23.i1.93] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
7 Akhmedov VA, Sargsyan AK, Gaus OV. Prospects for the use of biomarkers in the diagnosis of irritable bowel syndrome. jour 2020. [DOI: 10.31146/1682-8658-ecg-175-3-94-101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Xu W, Yuan M, Wu X, Geng H, Chen L, Zhou J, Song Y, Pei L, Sun J. Electroacupuncture Relieves Visceral Hypersensitivity by Inactivating Protease-Activated Receptor 2 in a Rat Model of Postinfectious Irritable Bowel Syndrome. Evid Based Complement Alternat Med 2018;2018:7048584. [PMID: 30420896 DOI: 10.1155/2018/7048584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Paul M, Murphy SF, Hall C, Schaeffer AJ, Thumbikat P. Protease-activated receptor 2 activates CRAC-mediated Ca2+ influx to cause prostate smooth muscle contraction. FASEB Bioadv 2019;1:255-64. [PMID: 31198907 DOI: 10.1096/fba.2018-00024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gottesman-Katz L, Latorre R, Vanner S, Schmidt BL, Bunnett NW. Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system. Gut 2021;70:970-81. [PMID: 33272979 DOI: 10.1136/gutjnl-2020-321193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Videlock EJ, Mahurkar-Joshi S, Hoffman JM, Iliopoulos D, Pothoulakis C, Mayer EA, Chang L. Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. Am J Physiol Gastrointest Liver Physiol 2018;315:G140-57. [PMID: 29565640 DOI: 10.1152/ajpgi.00288.2017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
12 Edgington-Mitchell LE. Pathophysiological roles of proteases in gastrointestinal disease. Am J Physiol Gastrointest Liver Physiol. 2016;310:G234-G239. [PMID: 26702140 DOI: 10.1152/ajpgi.00393.2015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
13 Singh P, Grabauskas G, Zhou SY, Gao J, Zhang Y, Owyang C. High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation. JCI Insight 2021;6:e146529. [PMID: 34618688 DOI: 10.1172/jci.insight.146529] [Reference Citation Analysis]
14 Su J, Duan X, Qiu Y, Zhou L, Zhang H, Gao M, Liu Y, Zou Z, Qiu J, Chen C. Pregnancy exposure of titanium dioxide nanoparticles causes intestinal dysbiosis and neurobehavioral impairments that are not significant postnatally but emerge in adulthood of offspring. J Nanobiotechnology 2021;19:234. [PMID: 34362405 DOI: 10.1186/s12951-021-00967-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Holland AM, Bon-Frauches AC, Keszthelyi D, Melotte V, Boesmans W. The enteric nervous system in gastrointestinal disease etiology. Cell Mol Life Sci 2021;78:4713-33. [PMID: 33770200 DOI: 10.1007/s00018-021-03812-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Uranga JA, Martínez V, Abalo R. Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use. Molecules 2020;25:E4314. [PMID: 32962285 DOI: 10.3390/molecules25184314] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Diao J, Xia Y, Jiang X, Qiu J, Cheng S, Su J, Duan X, Gao M, Qin X, Zhang J, Fan J, Zou Z, Chen C. Silicon dioxide nanoparticles induced neurobehavioral impairments by disrupting microbiota-gut-brain axis. J Nanobiotechnology 2021;19:174. [PMID: 34112173 DOI: 10.1186/s12951-021-00916-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Choo J, Heo G, Pothoulakis C, Im E. Posttranslational modifications as therapeutic targets for intestinal disorders. Pharmacol Res 2021;165:105412. [PMID: 33412276 DOI: 10.1016/j.phrs.2020.105412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]